Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22370379 | 1.00 | BIRC2 (0.32) | BIRC2CA12CA14 | |
| SCHEMBL22370377 | 1.00 | BIRC2 (0.32) | BIRC2CA12CA14 | |
| SCHEMBL22370542 | 0.86 | — | — | |
| SCHEMBL22370544 | 0.86 | — | — | |
| SCHEMBL15228718 | 0.82 | CTSK (0.40) | CA12CA14 | |
| SCHEMBL7056042 | 0.82 | CTSK (0.40) | CA12CA14 | |
| SCHEMBL26207740 | 0.82 | CTSK (0.40) | CA12CA14 | |
| SCHEMBL22527160 | 0.82 | CTSK (0.40) | CA12CA14 | |
| SCHEMBL15228716 | 0.82 | CTSK (0.40) | CA12CA14 | |
| SCHEMBL22388216 | 0.81 | CA12 (0.33) | BIRC2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-111491938-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3710458-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| CN-111491938-A | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2020-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | BIRC2 1510/4885CA12 2356/4885CA14 2583/4885 |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | BIRC2 1510/4885CA12 2356/4885CA14 2583/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | BIRC2 1510/4885CA12 2356/4885CA14 2583/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | BIRC2 1510/4885CA12 2356/4885CA14 2583/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | BIRC2 1510/4885CA12 2356/4885CA14 2583/4885 |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | BIRC2 1510/4885CA12 2356/4885CA14 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.